Experience and enlightenment of out-of-hospital pharmacy management under the 340B drug pricing program in the United States
- VernacularTitle:美国340B药品定价计划下院外药房管理的经验与启示
- Author:
Yueming JIA
1
,
2
;
Lai JIANG
2
,
3
;
Lanting LYU
2
Author Information
1. Dept. of Pharmacy，OASIS International Hospital，Beijing 100015，China
2. Center for Health Technology Assessment and Policy Evaluation，Renmin University of China，Beijing 100872，China
3. School of Public Administration and Policy，Renmin University of China，Beijing 100872，China
- Publication Type:Journal Article
- Keywords:
340B drug pricing program;
dual-channel
- From:
China Pharmacy
2023;34(8):897-901
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To learn from 340B drug pricing program （short for 340B program） in the United States， and provide reference for optimizing the operation and management of designated retail pharmacies under the “dual channel” policy in China. METHODS The status quos of the implementation of out-of-hospital pharmacies under the 340B program in the United States was reviewed to summarize the experience of the management of out-of-hospital pharmacies under the program in the United States， and to propose thoughts of management and possible problems for designated retail pharmacies under the “dual channel” policy in China. RESULTS & CONCLUSIONS Out-of-hospital pharmacies under the 340B program lacked sufficient basic information and medical insurance status of patients compared to medical institutions， which easily led to duplicate discounts and drug diversion issues. Due to the separation of out-of-hospital pharmacies from the management and restrictions on the use of drugs in medical institutions， coupled with the economic incentives brought by the sale of drugs， the 340B program in the United States faced high medical expenditure and adverse selection risks for out-of-hospital pharmacies. In this regard， when China is carrying out the construction of designated retail pharmacies under the “dual channel” policy， it is necessary to clarify the selection criteria for designated retail pharmacies， enhance the financial transparency of medical institutions and designated retail pharmacies， establish a scientific prescription circulation mechanism， strengthen the review and certification of insured patients and prescriptions， and improve the supervision and management mechanism. Meanwhile， the drug sales situation of designated retail pharmacies should be reasonably incorporated into the drug use management of medical institutions， so as to achieve the availability of drugs without abuse， and effectively control costs.
